Open access
Open access
Powered by Google Translator Translator

Chest Medicine (all articles)

Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).

7 Sep, 2021 | 10:45h | UTC

Immunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD

 

More data showing increased risk of hospitalization with SARS-CoV-2 delta variant.

6 Sep, 2021 | 11:12h | UTC

Hospitalisation associated with SARS-CoV-2 delta variant in Denmark – The Lancet Infectious Diseases

Related study: Cohort study: Patients with Covid-19 infected with the Delta variant are twice as likely to need hospital admission or emergency care attendance.

 

The resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce; vaccine effectiveness against infection was reduced from above 90% from March through June to 65% in July.

6 Sep, 2021 | 11:09h | UTC

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce – New England Journal of Medicine

Related:

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

Study shows AstraZeneca and Pfizer vaccines are effective against Delta variant, but both doses are needed.

 

Commentary on Twitter (thread – click for more)

 

RCT: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels.

6 Sep, 2021 | 11:11h | UTC

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial – Nature Medicine

 

Commentary on Twitter

 

Large surveillance study finds severe adverse events after COVID-19 mRNA vaccination are rare.

6 Sep, 2021 | 11:02h | UTC

Surveillance for Adverse Events After COVID-19 mRNA Vaccination – JAMA

Editorial: Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink – JAMA

Commentaries:

mRNA COVID vaccines not tied to serious side effects – CIDRAP

Researchers find no serious health effects linked to mRNA COVID-19 vaccines – News Medical

 

Commentary on Twitter

 

Interactive infographic showing the effects of Delta: How coronavirus spreads through a population and how we can beat it.

6 Sep, 2021 | 10:59h | UTC

How coronavirus spreads through a population and how we can beat it – The Guardian

 

Double vaccination halves risk of Long COVID.

3 Sep, 2021 | 10:29h | UTC

News release: Double vaccination halves risk of Long COVID – King’s College London

Original study: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study – The Lancet Infectious Diseases

Commentaries:

Largest study of its kind finds face masks reduce COVID-19 – University of California – Berkeley

Study: Vaccines slash long-haul COVID, hospital rates – CIDRAP

Vaccination reduces risk of long Covid, even when people are infected, U.K. study indicates – STAT

Being fully vaccinated reduces odds of long-term Covid-19 symptoms by half, UK study suggests – CNN

Coronavirus vaccines cut risk of long Covid, study finds – BBC

Related: M-A: More than 50 long-term effects of COVID-19.

 

Commentary on Twitter

 

WHO says it is monitoring a new Covid variant called ‘mu’.

3 Sep, 2021 | 10:21h | UTC

WHO says it is monitoring a new Covid variant called ‘mu’ – CNBC

See also:

What’s the Mu variant? And will we keep seeing more concerning variants? – The Conversation

WHO monitoring new coronavirus variant named ‘Mu’ – France 24

New ‘mu’ coronavirus variant could escape vaccine-induced immunity, WHO says – LiveScience

WHO monitoring new coronavirus variant named Mu – The Guardian

 

[Preprint] Largest study of masks yet details their importance in fighting Covid-19.

3 Sep, 2021 | 10:30h | UTC

Largest study of masks yet details their importance in fighting Covid-19 – NBC News

Original study: The Impact of Community Masking on COVID-19: A Cluster-Randomized Trial in Bangladesh – Innovations for Poverty Action

See also: A Study In Bangladesh Tripled The Rate Of Mask-Wearing. Can It Help In The U.S.? – NPR

 

Commentaries on Twitter (thread – click for more)

(thread from the author – click for more)

 

EU agency says to focus on vaccines first not booster shots.

3 Sep, 2021 | 10:34h | UTC

EU agency says to focus on vaccines first not booster shots – Associated Press

See also: European officials say COVID-19 booster isn’t urgent – CIDRAP

 

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

2 Sep, 2021 | 10:17h | UTC

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial – The Lancet Respiratory Medicine

Commentaries:

Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial – The Lancet Respiratory Medicine

Rheumatoid Arthritis Drug Combined with Standard of Care May Help Reduce Mortality for Hospitalized COVID-19 Patients – Vanderbilt University Medical Center

 

Commentaries on Twitter

(thread – click for more)

 

Review | COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.

2 Sep, 2021 | 10:06h | UTC

COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses – The Lancet Rheumatology

 

Commentary on Twitter

 

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

2 Sep, 2021 | 10:05h | UTC

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar – medRxiv

Related:

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 

Commentary on Twitter (thread – click for more)

 

RCT: Among critically ill patients, targeting oxygenation to a low-normal range vs. high-normal range did not result in a reduction in organ dysfunction.

2 Sep, 2021 | 08:23h | UTC

Effect of Low-Normal vs High-Normal Oxygenation Targets on Organ Dysfunction in Critically Ill Patients: A Randomized Clinical Trial – JAMA (free for a limited period)

Related:

M-A of randomized trials: Conservative oxygen therapy for critically ill patients.

Oxygen administration for patients with ARDS – Journal of Intensive Care

Randomized trial: Similar outcomes with lower vs. higher oxygenation targets for acute hypoxemic respiratory failure

Systematic Review: Higher vs. Lower Fraction of Inspired Oxygen or Targets of Arterial Oxygenation for Adults Admitted to the Intensive Care Unit

 

Commentary on Twitter

 

RCT: In patients with acute hypoxemic respiratory failure, a strategy of lower tidal volume ventilation facilitated by extracorporeal carbon dioxide removal was not associated with improved outcomes.

2 Sep, 2021 | 08:21h | UTC

Effect of Lower Tidal Volume Ventilation Facilitated by Extracorporeal Carbon Dioxide Removal vs Standard Care Ventilation on 90-Day Mortality in Patients With Acute Hypoxemic Respiratory Failure: The REST Randomized Clinical Trial – JAMA (free for a limited period)

Related: Randomized Trial: Low vs Intermediate Tidal Volume Strategy in ICU Patients Without ARDS

 

Commentary on Twitter

 

[Preprint] Pfizer vaccine booster dose protection: A nationwide study from Israel – “Twelve days or more after the booster dose we found an 11.4-fold decrease in the relative risk of confirmed infection, and a >10-fold decrease in the relative risk of severe illness”.

1 Sep, 2021 | 09:59h | UTC

BNT162b2 vaccine booster dose protection: A nationwide study from Israel – medRxiv

 

Why is a third COVID-19 vaccine dose important for people who are immunocompromised?

1 Sep, 2021 | 09:57h | UTC

Why is a third COVID-19 vaccine dose important for people who are immunocompromised? – The Conversation

Related:

FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.

RCT: third dose of Moderna mRNA vaccine increases immunity in transplant recipients.

Study: Among kidney transplant recipients who did not respond after 2 doses, a third dose of an mRNA-1273 vaccine induced a serologic response in 49% of patients.

Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.

 

COVID may be most infectious 2 or 3 days around symptom onset.

1 Sep, 2021 | 09:51h | UTC

COVID may be most infectious 2 or 3 days around symptom onset – CIDRAP

Original article: COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With COVID-19: A Population-Based Cohort Study in Zhejiang Province, China – JAMA Internal Medicine

 

Study: Patients, not staff, source of most hospital COVID spread.

1 Sep, 2021 | 09:52h | UTC

Study: Patients, not staff, source of most hospital COVID spread – CIDRAP

Original article: Superspreaders drive the largest outbreaks of hospital onset COVID-19 infections – eLife

 

Cohort study: A strategy combining a rapid antigen test and chest CT was effective in ruling out COVID-19 in the emergency department.

31 Aug, 2021 | 09:00h | UTC

Rapid Antigen Test Combined with Chest Computed Tomography to Rule Out COVID-19 in Patients Admitted to the Emergency Department – Journal of Clinical Medicine

 

Study demonstrates a significantly higher humoral immunogenicity induced by the SARS-CoV-2 Moderna vaccine compared with the Pfizer- BioNTech vaccine.

31 Aug, 2021 | 09:04h | UTC

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273 – JAMA

Related:

Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.

[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7% for Pfizer and 100.0% for Moderna.

 

#ESCCongress – RCT: Influenza vaccination early after a myocardial infarction (MI) or in high-risk coronary heart disease resulted in a lower risk of a composite of all-cause death, MI, or stent thrombosis compared with placebo.

31 Aug, 2021 | 08:52h | UTC

Influenza Vaccination after Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial – Circulation

Commentaries:

IAMI: Influenza Vaccine Beneficial for Post-MI Patients – TCTMD

Influenza Vaccination After Myocardial Infarction – IAMI – American College of Cardiology

Flu vaccine after heart attack reduces risk of death – Cardiovascular Business

 

Commentary on Twitter

 

Study with over 29 million people in England shows Covid-19, not vaccination, presents biggest blood clot risks.

29 Aug, 2021 | 18:57h | UTC

Press release: Covid-19, not vaccination, presents biggest blood clot risks – University of Oxford

Original study: Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study – The BMJ

Editorial: Strengthening international surveillance of vaccine safety – The BMJ

Commentaries:

Expert reaction to study looking at risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 infection – Science Media Centre

Covid: Vaccine complications dwarfed by virus risks – BBC

 

Commentary on Twitter

 

Cohort study: Patients with Covid-19 infected with the Delta variant are twice as likely to need hospital admission or emergency care attendance.

29 Aug, 2021 | 19:02h | UTC

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study – The Lancet Infectious Diseases

Commentaries:

Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants – The Lancet Infectious Diseases

Covid: Delta variant patients twice as likely to need hospital care – BBC

Covid-19 hospitalization risk doubles with Delta variant, UK study suggests – CNN

Expert reaction to study looking at risk of hospitalisation from the delta variant compared with alpha – Science Media Centre

 

Commentary on Twitter

 

M-A: Factors associated with household transmission of SARS-CoV-2 – recent studies showed higher household secondary attack rates than earliest reports (13.4% vs. 31.1%); more transmissible variants and vaccines may lead to further changes.

29 Aug, 2021 | 18:48h | UTC

Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis – JAMA Network Open

Commentary: 1 in 5 people with COVID-19 pass it to others in household, study finds – UPI

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.